Soliris 300mg

FOB Price: USD 2800 - 3200
|
5 Boxes (Min. Order)
  • Supplying Ability100 Boxes Per Week
  • Supplying TypeIn stock
  • Model NumberPL2645/2
  • Preferred Payment Method:T/T

RCC Pharma AG

United Kingdom

Port: Hethrow airport

Quick Details

  • Batch No: PL2645/2:Expiry date: 03/2021
  • Processing Time:3 days
  • Port:Hethrow airport
  • Supply Ability: 100 Boxes Per Week
  • Brand Name:soliris 300mg
Soliris 30mg is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease. Its use and Indications Soliris is indicated for The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy. Treatment For treatment related information, please consult your treating Physician. How supplied: Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution. Storage and handling Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light. DO NOT FREEZE, DO NOT SHAKE How do we source the Drug? Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential. Soliris 30mg is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease. Its use and Indications Soliris is indicated for The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy. Treatment For treatment related information, please consult your treating Physician. How supplied: Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution. Storage and handling Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light. DO NOT FREEZE, DO NOT SHAKE How do we source the Drug? RCC Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.